CA2960830C - Detection of misfolded proteins - Google Patents

Detection of misfolded proteins Download PDF

Info

Publication number
CA2960830C
CA2960830C CA2960830A CA2960830A CA2960830C CA 2960830 C CA2960830 C CA 2960830C CA 2960830 A CA2960830 A CA 2960830A CA 2960830 A CA2960830 A CA 2960830A CA 2960830 C CA2960830 C CA 2960830C
Authority
CA
Canada
Prior art keywords
protein
misfolded
soluble
incubation mixture
incubation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2960830A
Other languages
English (en)
French (fr)
Other versions
CA2960830A1 (en
Inventor
Claudio Soto JARA
Mohammad Shahnawaz
Russell M. Lebovitz
Benedikt K. VOLLRATH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Amprion Inc
Original Assignee
University of Texas System
Amprion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, Amprion Inc filed Critical University of Texas System
Publication of CA2960830A1 publication Critical patent/CA2960830A1/en
Application granted granted Critical
Publication of CA2960830C publication Critical patent/CA2960830C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
CA2960830A 2014-09-11 2015-09-11 Detection of misfolded proteins Active CA2960830C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462049306P 2014-09-11 2014-09-11
US62/049,306 2014-09-11
PCT/US2015/049844 WO2016040907A1 (en) 2014-09-11 2015-09-11 Detection of misfolded proteins

Publications (2)

Publication Number Publication Date
CA2960830A1 CA2960830A1 (en) 2016-03-17
CA2960830C true CA2960830C (en) 2023-09-05

Family

ID=55454515

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2960830A Active CA2960830C (en) 2014-09-11 2015-09-11 Detection of misfolded proteins

Country Status (15)

Country Link
US (1) US20160077112A1 (US07794700-20100914-C00194.png)
EP (2) EP4292654A3 (US07794700-20100914-C00194.png)
JP (2) JP6980953B2 (US07794700-20100914-C00194.png)
KR (1) KR102448128B1 (US07794700-20100914-C00194.png)
CN (1) CN107208125A (US07794700-20100914-C00194.png)
AU (1) AU2015314783B2 (US07794700-20100914-C00194.png)
BR (1) BR112017004899A2 (US07794700-20100914-C00194.png)
CA (1) CA2960830C (US07794700-20100914-C00194.png)
ES (1) ES2953855T3 (US07794700-20100914-C00194.png)
HR (1) HRP20231232T1 (US07794700-20100914-C00194.png)
IL (2) IL251052B (US07794700-20100914-C00194.png)
MX (1) MX2017003269A (US07794700-20100914-C00194.png)
PL (1) PL3191599T3 (US07794700-20100914-C00194.png)
SG (2) SG11201701953RA (US07794700-20100914-C00194.png)
WO (1) WO2016040907A1 (US07794700-20100914-C00194.png)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10989718B2 (en) 2014-09-11 2021-04-27 Amprion, Inc. Detection of misfolded alpha synuclein protein
GB201611840D0 (en) * 2016-07-07 2016-08-24 Univ Court Of The Univ Of Edinburgh The Alpha-synuclein detection assay
CN110506057B (zh) 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
MX2019013589A (es) 2017-05-16 2020-07-20 Claudio Soto Jara Deteccion de proteina tau con plegamiento incorrecto.
WO2019070480A1 (en) * 2017-10-02 2019-04-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ASSAY FOR DETECTION OF ALPHA-SYNUCLEIN SELF-ACTIVATION ACTIVITY ASSOCIATED WITH SYNUCLEINOPATHIES
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
EP3729088B1 (en) * 2017-12-21 2021-10-20 H. Lundbeck A/S Diagnosis and treatment of alpha-synucleinopathies
CN108088816A (zh) * 2018-01-23 2018-05-29 深圳市国赛生物技术有限公司 小型特定蛋白分析仪
GB201803553D0 (en) 2018-03-06 2018-04-18 Univ Newcastle Detection of pathological protein aggregation
US20190353669A1 (en) * 2018-05-16 2019-11-21 Amprion, Inc. Detection of Brain Injury or Neurological Disease using Tau Protein
EP3821433B1 (en) * 2018-09-21 2024-06-05 DeepMind Technologies Limited Iterative protein structure prediction using gradients of quality scores
JP7376040B2 (ja) * 2019-09-03 2023-11-08 国立大学法人京都工芸繊維大学 神経変性疾患におけるバイオマーカー分子の検出方法
CN115003824A (zh) 2019-09-04 2022-09-02 安培里翁公司 使用珠子检测α-突触核蛋白
KR102277871B1 (ko) * 2019-12-17 2021-07-15 원광대학교산학협력단 소변의 알파-씨누클레인 중합체 측정에 의한 파킨슨병 진단 정보의 수집방법 및 그 키트
WO2021198098A1 (en) 2020-04-03 2021-10-07 Universität Zürich Improved method of detecting biomarkers in a biological sample
US20240003909A1 (en) * 2020-11-21 2024-01-04 Xingmin Li Apparatus and method for detecting misfolded protein in biological sample
US20240192230A1 (en) * 2021-04-15 2024-06-13 The Brigham And Women’S Hospital, Inc. Digital Protein Misfolding Assays
CN114199875B (zh) * 2022-02-18 2022-05-20 之江实验室 一种蛋白质多聚体是否可作为力缓冲剂的判断方法及装置

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05675B1 (et) 2000-07-07 2013-08-15 Applied Research Systems Ars Holding N.V. Meetod konformse haiguse diagnoosimiseks v?i tuvastamiseks, selleks vajalik katsemenetlus, reaktiivikomplekt ning seade
US20030027210A1 (en) * 2001-01-03 2003-02-06 Daniel Benjamin Alpha synuclein aggregation assays
GB0203446D0 (en) * 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
EP1820806A1 (en) * 2006-02-16 2007-08-22 Crossbeta Biosciences B.V. Affinity regions
JP5048522B2 (ja) * 2005-02-15 2012-10-17 エイディーライフ インコーポレイティッド 誤って折り畳まれたタンパク質およびプリオンを検出する方法
EP2392583A1 (en) * 2006-05-19 2011-12-07 Alnylam Europe AG. RNAi modulation of Aha and therapeutic uses thereof
US20080118938A1 (en) * 2006-09-06 2008-05-22 Lisbell Estrada Methods and Compositions for the Detection of Protein Folding Disorders
JP2010043865A (ja) * 2006-12-12 2010-02-25 Olympus Corp 異常型プリオンの検出方法
JP2013511734A (ja) * 2009-11-24 2013-04-04 プロビオドルグ エージー アルツハイマー病又は軽度認知障害の診断のための新規診断方法
US9133343B2 (en) * 2009-11-30 2015-09-15 Enzo Biochem, Inc. Dyes and compositions, and processes for using same in analysis of protein aggregation and other applications
US9910049B2 (en) * 2014-09-11 2018-03-06 Amprion, Inc. Detection of misfolded amyloid beta protein
US20130288389A1 (en) * 2011-01-18 2013-10-31 Prionics Ag Methods for amplification and detection of prions
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof

Also Published As

Publication number Publication date
PL3191599T3 (pl) 2023-12-27
WO2016040907A1 (en) 2016-03-17
CA2960830A1 (en) 2016-03-17
SG11201701953RA (en) 2017-04-27
EP3191599A1 (en) 2017-07-19
AU2015314783B2 (en) 2021-10-21
MX2017003269A (es) 2017-12-04
JP7104943B2 (ja) 2022-07-22
US20160077112A1 (en) 2016-03-17
SG10202008464UA (en) 2020-10-29
JP2017530373A (ja) 2017-10-12
IL291809B2 (en) 2023-06-01
HRP20231232T1 (hr) 2024-01-19
KR102448128B1 (ko) 2022-09-27
EP4292654A3 (en) 2024-01-03
EP3191599A4 (en) 2018-03-14
JP2022000629A (ja) 2022-01-04
EP3191599C0 (en) 2023-08-02
BR112017004899A2 (pt) 2017-12-12
AU2015314783A1 (en) 2017-04-27
EP4292654A2 (en) 2023-12-20
KR20170103741A (ko) 2017-09-13
EP3191599B1 (en) 2023-08-02
IL251052B (en) 2022-05-01
JP6980953B2 (ja) 2021-12-15
CN107208125A (zh) 2017-09-26
IL251052A0 (en) 2017-04-30
ES2953855T3 (es) 2023-11-16
IL291809A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
CA2960830C (en) Detection of misfolded proteins
US20210208166A1 (en) Detection of Misfolded Alpha Synuclein Protein
US9910049B2 (en) Detection of misfolded amyloid beta protein
US20220137073A1 (en) Detection of misfolded tau protein
Mair et al. FLEXITau: quantifying post-translational modifications of tau protein in vitro and in human disease
AU2007278422A1 (en) Method for the detection of amyloid-beta oligomers in body fluids
Lattanzi et al. Solubility of Aβ40 peptide
US20210102961A1 (en) Detection of misfolded proteins
US20190137515A1 (en) Methods for estimating misfolded protein concentration in fluids and tissue by quantitative pmca
US20190353669A1 (en) Detection of Brain Injury or Neurological Disease using Tau Protein
WO2013056841A1 (en) A method for diagnosing tse
Funke et al. Detection and quantitation of Amyloid-β aggregates in body fluids may be suitable for early diagnosis of Alzheimer’s disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180911

EEER Examination request

Effective date: 20180911

EEER Examination request

Effective date: 20180911

EEER Examination request

Effective date: 20180911

EEER Examination request

Effective date: 20180911

EEER Examination request

Effective date: 20180911

EEER Examination request

Effective date: 20180911

EEER Examination request

Effective date: 20180911